36 results on '"Bjerre, Karsten"'
Search Results
2. Correlation of High Seawater Temperature with Vibrio and Shewanella Infections, Denmark, 2010–2018
3. Epidemiological and microbiological investigation of a large increase in vibriosis, northern Europe, 2018
4. The Influence of Repeat Surgery and Residual Disease on Recurrence After Breast-Conserving Surgery: A Danish Breast Cancer Cooperative Group Study
5. A Nationwide Observational Study of Chlamydia trachomatis Infections in Denmark during the COVID-19 Pandemic
6. Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy
7. Epidemiological and microbiological investigation of the large increase of vibriosis in northern Europe in 2018
8. A nationwide study of Chlamydia trachomatis infections in Denmark during the COVID-19 pandemic
9. Importance of Margin Width in Breast-Conserving Treatment of Early Breast Cancer
10. A nationwide study of Chlamydia trachomatis infections in Denmark during the COVID-19 pandemic
11. Mortality Rates Among Early-Stage Hormone Receptor–Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark
12. Are unexplained adverse health events following HPV vaccination associated with infectious mononucleosis? – A Danish nationwide matched case-control study
13. Assessment of Ki67 in breast cancer:A quality assurance study of the Danish Scientific Committee of Pathology, on behalf of DBCG, in collaboration with the Swedish Breast Pathology Group
14. First Line therapy of metasttic or locally advanced HER2-positive breast cancer. Update of the HERNATA study
15. P95HER2 as a predictive marker in the phase III randomized HERNATA trial of trastuzumab and chemotherapy as first-line therapy to metastatic or locally advanced HER2-positive breast cancer.
16. Site-specific management of crop disease
17. TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
18. PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients
19. Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
20. PO57 COMPARISON OF DOCETAXEL PLUS TRASTUZUMAB (DT) AND VINORELBINE PLUS TRASTUZUMAB (VT) AS FIRST-LINE THERAPY OF ANTHRACYCLINE PRE-TREATED METASTATIC OR LOCALLY ADVANCED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER (A SUB-GROUP ANALYSIS OF THE HERNATA STUDY)
21. Sygdomskort og positions-bestemt fungicidanvendelse
22. Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer
23. Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy
24. Breast cancer survival and season of surgery: an ecological open cohort study
25. Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group
26. Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1
27. Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
28. The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study
29. Classical pathological variables recorded in the Danish Breast Cancer Cooperative Group's register 1978–2006
30. Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG Registry
31. Recurrence pattern and prognosis in low-risk breast cancer patients – Data from the DBCG 89-A programme
32. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise
33. Chapter 7: Site-Specific Management of Crop Diseases.
34. TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.
35. PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.
36. Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.